These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 32535128)

  • 1. Are lupus animal models useful for understanding and developing new therapies for human SLE?
    Moore E; Putterman C
    J Autoimmun; 2020 Aug; 112():102490. PubMed ID: 32535128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE.
    van Dam LS; Osmani Z; Kamerling SWA; Kraaij T; Bakker JA; Scherer HU; Rabelink TJ; Voll RE; Alexander T; Isenberg DA; van Kooten C; Teng YKO
    Rheumatology (Oxford); 2020 Oct; 59(10):2734-2745. PubMed ID: 31951278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus.
    Hui-Yuen JS; Nguyen SC; Askanase AD
    Lupus; 2016 Sep; 25(10):1086-96. PubMed ID: 27497253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
    Mosak J; Furie R
    Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B cell alterations during BAFF inhibition with belimumab in SLE.
    Ramsköld D; Parodis I; Lakshmikanth T; Sippl N; Khademi M; Chen Y; Zickert A; Mikeš J; Achour A; Amara K; Piehl F; Brodin P; Gunnarsson I; Malmström V
    EBioMedicine; 2019 Feb; 40():517-527. PubMed ID: 30593436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.
    Zhang H; Chambers W; Sciascia S; Cuadrado MJ
    Expert Rev Clin Pharmacol; 2016; 9(5):681-94. PubMed ID: 26907827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapeutic avenues in SLE.
    Bakshi J; Ismajli M; Rahman A
    Best Pract Res Clin Rheumatol; 2015 Dec; 29(6):794-809. PubMed ID: 27107514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy.
    Bela MM; Espinosa G; Cervera R
    Lupus; 2021 Jan; 30(1):134-140. PubMed ID: 33081591
    [No Abstract]   [Full Text] [Related]  

  • 11. Belimumab for systemic lupus erythematosus: a practice-based view.
    Parodis I; Axelsson M; Gunnarsson I
    Lupus; 2013 Apr; 22(4):372-80. PubMed ID: 23553780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of systemic lupus erythematosus: myths, certainties and doubts].
    Ruiz-Irastorza G; Danza A; Khamashta M
    Med Clin (Barc); 2013 Dec; 141(12):533-42. PubMed ID: 23622892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current role of rituximab in systemic lupus erythematosus.
    Mok CC
    Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New biologic therapy for systemic lupus erythematosus.
    Ding HJ; Gordon C
    Curr Opin Pharmacol; 2013 Jun; 13(3):405-12. PubMed ID: 23664092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP; D'Cruz DP
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.
    Sthoeger Z; Sharabi A; Mozes E
    J Autoimmun; 2014 Nov; 54():60-71. PubMed ID: 24958634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologics in SLE: towards new approaches.
    van Vollenhoven RF; Parodis I; Levitsky A
    Best Pract Res Clin Rheumatol; 2013 Jun; 27(3):341-9. PubMed ID: 24238691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When to use belimumab in SLE.
    Gatto M; Iaccarino L; Zen M; Doria A
    Expert Rev Clin Immunol; 2017 Aug; 13(8):737-740. PubMed ID: 28463023
    [No Abstract]   [Full Text] [Related]  

  • 19. New developments in the treatment of systemic lupus erythematosus.
    Tullus K
    Pediatr Nephrol; 2012 May; 27(5):727-32. PubMed ID: 21516516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [What's new in internal medicine: emerging treatments for systemic lupus erythematosus].
    Hachulla É
    Ann Dermatol Venereol; 2011 Dec; 138 Suppl 4():S241-4. PubMed ID: 22202645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.